Indicated for
- Treatment of hypertension.
- Treatment of symptomatic heart failure.
- Acute myocardial infarction
Short-term (6 weeks) treatment of haemodynamically stable patients within 24 hours of an acute myocardial infarction.
- Renal complications of diabetes mellitus
Treatment of renal disease in hypertensive patients with Type 2 diabetes mellitus and incipient nephropathy
Short-term treatment of all grades of pain and inflammation in the following acute conditions:
•Post-traumatic pain, inflammation and swelling, e.g. due to sprains.
• acute musculo-skeletal disorders such as periarthritis (for example frozen shoulder), tendonitis, tenosynovitis, bursitis
• Post-operative pain, inflammation and swelling, e.g. following dental or orthopaedic surgery.
• Painful and/or inflammatory conditions in gynaecology, e.g. primary dysmenorrhoea or adnexitis and associated menorrhagia.
• Migraine attacks.
• Acute gout
• Painful syndromes of the vertebral column.
• Non-articular rheumatism.
• As an adjuvant in severe painful inflammatory infections of the ear, nose or throat, e.g. pharyngotonsillitis, otitis.
Indicated for
- Treatment of Peripheral and central neuropathic pain in adults.
- As adjunctive therapy in adults with partial seizures with or without secondary generalisation.
- Treatment of Generalised Anxiety Disorder (GAD) in adults.
Broncast pediatric 5mg is indicated in the treatment of asthma as add-on therapy in those patients with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom “as needed” short-acting β-agonists provide inadequate clinical control of asthma.
Broncast pediatric 5mg may also be an alternative treatment option to low-dose inhaled corticosteroids for patients with mild persistent asthma who do not have a recent history of serious asthma attacks that required oral corticosteroid use, and who have demonstrated that they are not capable of using inhaled corticosteroids
Broncast pediatric 5mg is also indicated in the prophylaxis of asthma in which the predominant component is exercise-induced bronchoconstriction.
Broncast pediatric 5mg is indicated for the relief of symptoms of seasonal allergic rhinitis and perennial allergic rhinitis in patients 6 years of age and older.
Soluvit N is indicated in adult patients and children as a supplement in intravenous nutrition to meet the daily requirements of water-soluble vitamins
Darunavir, co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV-1) infection.
Darunavir, co-administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg)
Darunavir 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of HIV-1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:
Antiretroviral therapy (ART)-naïve
• ART-experienced with no darunavir resistance associated mutations (DRV-RAMs) and who have plasma HIV-1 RNA < 100,000 copies/ml and CD4+ cell count ≥ 100 cells x 106/L. In deciding to initiate treatment with darunavir in such ART-experienced patients, genotypic testing should guide the use of darunavir
